FDA Signals Generative AI Device Guidance Is Coming

The FDA is preparing to tell industry how it will regulate generative AI in medical devices. Rick Abramson, the agency's head of digital health policy, said guidance on generative AI devices is coming, according to STAT News.

The signal matters because the FDA's existing playbook was designed for narrow, fixed-function algorithms that behave predictably. Generative models are different: they produce open-ended outputs, can drift over time, and are harder to validate against a single intended use. Hundreds of AI-enabled devices have already cleared the agency, but almost none rely on the large language models now flooding into clinical documentation, decision support, and patient-facing tools. That has left developers guessing about what evidence and controls regulators will expect.

Abramson did not commit to a firm timeline or detail the contents. For builders and health systems deploying generative AI, the coming guidance could clarify testing, monitoring, and labeling requirements, and shape which products need FDA review at all. Until it lands, much of the market operates in a gray zone.